Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.67 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.60 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | HRH1 | P35367 | 1/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.58 |
| ▸ | HTR2C | P28335 | 5/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.58 |
| ▸ | NCF1 | P14598 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | USP2 | O75604 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29936658 | 1.00 | PTK2 (0.67) | PTK2HRH4HTTLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2797449 | 0.98 | PTK2 (0.65) | PTK2HRH4HTTLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL30059021 | 0.98 | PTK2 (0.65) | PTK2HRH4HTTLMNASMN1; SMN2 | |
| Hydrazine SCHEMBL2797134 | 0.97 | PTK2 (0.63) | PTK2HRH4HTTLMNASMN1; SMN2 | |
| SCHEMBL5235576 | 0.94 | PTK2 (0.60) | PTK2HRH4HTTLMNASMN1; SMN2 | |
| SCHEMBL11015775 | 0.84 | PTK2 (0.73) | PTK2HRH4HTTLMNASMN1; SMN2 | |
| SCHEMBL30821993 | 0.83 | PTK2 (0.71) | PTK2HRH4HTTLMNASMN1; SMN2 | |
| SCHEMBL6569122 | 0.83 | PTK2 (0.71) | PTK2HRH4HTTLMNASMN1; SMN2 | |
| SCHEMBL2203931 | 0.81 | PTK2 (0.69) | PTK2HRH4HTTLMNASMN1; SMN2 | |
| SCHEMBL29974523 | 0.81 | PTK2 (0.56) | PTK2HRH4HTTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142506-B1 | NOVEL BENZOPHENONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2013-10-16 | — | — | EP | claimed |
| US-8394954-B2 | Benzophenone hybrids as anticancer agents and processes for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-03-12 | — | — | US | claimed |
| US-8309726-B2 | Substituted piperazine compounds of formula 8 | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-11-13 | — | — | US | claimed |
| EP-2150527-B1 | ANTHRANILIC ACID DERIVATIVE AS ANTICANCER AGENT AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2011-01-19 | — | — | EP | claimed |
| US-20100174074-A1 | NOVEL BENZOPHENONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2010-07-08 | — | — | US | claimed |
| EP-2150527-A2 | ANTHRANILIC ACID DERIVATIVE AS ANTICANCER AGENT AND A PROCESS FOR THE PREPARATION THEREOF | Council of Scientific & Industrial Research (IN) | 2010-02-10 | — | — | EP | claimed |
| US-20100016589-A1 | Novel Anthranilic Acid Derivative as Potential Anticancer Agent and a Process for the Preparation Thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2010-01-21 | — | — | US | claimed |
| EP-2142506-A1 | NOVEL BENZOPHENONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | Council of Scientific&Industrial Research (IN) | 2010-01-13 | — | — | EP | claimed |
| WO-2008120235-A1 | NOVEL BENZOPHENONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2008-10-09 | — | — | WO | claimed |
| WO-2008114275-A2 | ANTHRANILIC ACID DERIVATIVES AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2008-09-25 | — | — | WO | claimed |
| US-12486255-B2 | Modulators of RAS GTPase | TOSK, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20240279206-A1 | Modulators of RAS GTPase | TOSK, INC. | 2024-08-22 | — | — | US | disclosed |
| US-11945803-B2 | Modulators of RAS GTPase | TOSK, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-20230127636-A1 | COMPOUNDS FOR TREATING ILK-MEDIATED DISEASES | THE CLEVELAND CLINIC FOUNDATION | 2023-04-27 | — | — | US | disclosed |
| US-11524945-B2 | Compounds for treating ILK-mediated diseases | THE CLEVELAND CLINIC FOUNDATION (US) | 2022-12-13 | — | — | US | disclosed |
| CN-88101642-A | Piperazinyl-heterogeneous ring compound | — | 1988-09-14 | — | — | CN | disclosed |
| EP-0000121-A1 | 6-(1-Piperazinyl)-quinoxaline, process for its preparation and pharmaceutical compositions thereof | MERCK & CO. INC. (US) | 1979-01-10 | — | — | EP | disclosed |
| US-4091098-A | SEROTONINMIMETIC ACTIVITY; ANORECTIC, ANTIDEPRESSANT, ANALGESIC, HYPNOTIC AGENTS | MERCK & CO., INC. (US) | 1978-05-23 | — | — | US | disclosed |
| US-4091101-A | ANORECTIC AGENTS | MERCK & CO., INC. (US) | 1978-05-23 | — | — | US | disclosed |
| US-4082845-A | SEROTONINMIMETICS USEFUL AS ANORECTIC, ANTIDEPRESSANT, ANALGESIC AND HYPNOTIC AGENTS | MERCK & CO., INC. (US) | 1978-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100174074-A1 | NOVEL BENZOPHENONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | TP53, RB1, MCL1 | PTK2 2522/4885HRH4 3842/4885HTT 2010/4885 |
| US-20230127636-A1 | COMPOUNDS FOR TREATING ILK-MEDIATED DISEASES | ILK, ITGB1, ITGA2B | PTK2 11/4885HRH4 4423/4885HTT 3590/4885 |
| US-12486255-B2 | Modulators of RAS GTPase | KRAS, HRAS, NRAS | PTK2 1557/4885HRH4 2831/4885HTT 1434/4885 |
| US-20100016589-A1 | Novel Anthranilic Acid Derivative as Potential Anticancer Agent and a Process for the Preparation Thereof | AADAC, API5, APEH | PTK2 2494/4885HRH4 270/4885HTT 4496/4885 |
| US-11945803-B2 | Modulators of RAS GTPase | KRAS, HRAS, NRAS | PTK2 1557/4885HRH4 2831/4885HTT 1434/4885 |
| US-20240279206-A1 | Modulators of RAS GTPase | KRAS, HRAS, NRAS | PTK2 1557/4885HRH4 2831/4885HTT 1434/4885 |
| US-11524945-B2 | Compounds for treating ILK-mediated diseases | ILK, ITGB1, ITGA2B | PTK2 11/4885HRH4 4423/4885HTT 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.